MPLT Stock Analysis: Buy, Sell, or Hold?
$13.00
-0.79 (-5.69%)
âŧ
5d:
-1.07%
30d:
+14.24%
90d:
-57.17%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When MPLT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MPLT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MPLT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MPLT is currently trading at $13.00, which is considered slightly high relative to its 30-day fair value range of $11.68 to $13.35.
Technical Outlook: Technically, MPLT is in a strong downtrend. Immediate support is located at $12.12, while resistance sits at $14.22. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: MPLT scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.54 (+104.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MPLT is in a strong downtrend. Immediate support is located at $12.12, while resistance sits at $14.22. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: MPLT scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.54 (+104.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$11.68 -
$13.35
Company Quality Score
31/100
(SELL)
Options IV Signal
55th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
43.8%
All Signals
- NEUTRAL: Options fairly priced (IV 55th percentile)
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 104.1% below Wall St target ($26.54)
- WARNING: Composite score 31/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.68 -
$13.35
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$2.31
(17.7%)
Support & Resistance Levels
Support Level
$12.12
Resistance Level
$14.22
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.94
Wall Street Target
$26.54
(+104.1%)
Share & Embed Analysis
Last updated: September 12, 2026 12:05 PM ET
Data refreshes hourly during market hours. Next update: 1:05 PM
Data refreshes hourly during market hours. Next update: 1:05 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MPLT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |